| abstract |
In a first aspect, the present invention relates to pharmaceutical compositions for the treatment of infections with mycobacteria wherein said mycobacteria are resistant to at least one of the following drugs: rifampicin, isoniazid, pyrazinamide, or ethambutol, in particular, said mycobacteria are Mycobacterium tuberculosis (Mtb) complex strains. That is, the present invention relates to pharmaceutical compositions comprising as an active ingredient hydrazone compounds that have high activity against drug resistant mycobacteria, and in particular, Mtb complex strains resistant to isoniazid and rifampicin (multidrug-resistant Mtb , MDR- Mtb ), or MDR- Mtb strains further being resistant to one of the injectable aminoglycosides amikacin, kanamycin or capreomycin, and to fluoroquinolones (extremely drug-resistant XDR- Mtb ). In a further aspect, the present invention relates to the use of said hydrazone compounds for the treatment of mycobacterial infections. Moreover, the present invention relates to a method for the treatment of mycobacterial infections, in particular, MDR or XDR tuberculosis comprising the step of administering to an individual in need thereof an effective amount of a hydrazone compound of general formula I. |